EGFR and non-small cell lung carcinoma: Li et al. reported strong EPHA2 enrichment by dasatinib [58], while Choi et al. not only confirmed that both gefitinib and erlotinib reciprocally regulated EPHA2 expression in TKI-sensitive LC cells, but also treated EGFR-mutant HCC827 cells with the recombinant EPHA2-Fc peptide, thus inhibiting anchorage-independent NSCLC cell growth [59].